Market Research Report
Global Erectile Dysfunction Market - 2019-2026
|Published by||DataM Intelligence||Product code||834583|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Erectile Dysfunction Market - 2019-2026|
|Published: May 1, 2019||Content info: 130-180 Pages||
The global erectile dysfunction market was worth the US $XX billion in 2018 and is expected to reach US $XX billion by 2026, at a CAGR of XX% during the forecast period.
Erectile Dysfunction (ED) is one of the most common male sexual health disorder. ED affects physical and psychosocial health and significantly impacts on the quality of life (QoL) of patients and their partners. The primary symptom of the condition is the inability to attain or maintain firm erection during sexual intercourse. The disease can be classified as two broad sub-types - psychogenic and organic. Organic ED is gradual in onset whereas psychogenic ED is typically acute in onset.
Treatment options for ED include pharmacotherapy, external devices, and surgical therapy. Pharmacotherapy includes oral (phosphodiesterase-5 [PDE5] inhibitors), intracavernosal injectables and intraurethral suppositories, and topical medications. External devices include vacuum constriction devices. Penile prosthesis implantation is typically considered as the last treatment resort if none of the other therapies are successful. Despite the availability of multiple treatment modalities, currently, there is a significant unmet need in the ED market, as most of the treatment modalities are capable to just to manage the disease but not to cure it. Efficacy rates of ED treatment modalities are satisfactory but not hold potential to permanently cure the disease, except for penile implant surgeries.
The condition is highly prevalent in men above 40 years. According to WHO, ED is a common male sexual health problem affecting men of all ages, especially the middle-aged men. Globally, over 150 million men worldwide were estimated to have been affected by ED in 1995, and this is projected to rise to 320 million by 2025, an increase of nearly 170 million men. Though the condition is highly prevalent, it is considered as one of the most underdiagnosed and undertreated conditions.
Rise in disease prevalence, advent of novel treatment modalities and improving treatment seeking rates owing to rise in treatment awareness will propel the market in forecast period.
Prevalence of ED and other associated disorders is anticipated to increase at a notable pace in the foreseeable future. Studies have demonstrated that over 80% of ED cases are caused by other co-morbid conditions including diseases such as benign prostate hyperplasia, diabetes, high blood pressure, and high cholesterol. The prevalence of the most chronic disease is increasing in both developing and developed countries, thus increasing the prevalence of ED. For instance - according to the International Diabetes Federation, the global prevalence of diabetes is set to reach 642 million by 2040 from around 415 million in 2015.
Advances in medical markedly widened the options for the treatment and management of ED. For instance, traditionally the mainstays for management of ED were limited to oral medications, injectables, suppositories, VCDs, and implants. However, technological advances have widened treatment modalities with advent treatment options including external penile support devices, penile vibrators, low-intensity extracorporeal shockwave therapies, improved penile prosthesis systems, and others. For instance, Viberect is a, portable penile vibrator, used to provoke penile erection in men with ED. Coloplast's Titan OTR inflatable penile prosthetics features a self-contained, fluid-filled system made from Bioflex and silicone. The One-touch release (OTR) touch pads allows easy and one-handed deflation. Overall, the increase in preferability of technologically advanced devices with improved features can boost the market growth in the forecast period.
Low-treatment seeking pool (especially in developing countries), generic erosion of blockbuster ED drugs such as Viagra, Cialis and Levitra are major factors restraining the market growth.
Based on therapy type, the market is broadly segmented as the global erectile dysfunction drug therapy and global erectile dysfunction device therapy. The drug therapy accounted for more than 80% of the market in 2018 and is anticipated to retain its global dominance by the end of the forecast period, despite significant generic erosion. The device therapy is anticipated to increase sustainably in the near future.
The ED drug therapy market further segmented as oral therapies, topical therapies, and intrauretheral suppositories and penile injection therapies. Oral therapies accounted for the predominant market share in 2018. Oral therapies are mainly comprised of PDE5 inhibitor drugs. The market value for oral PDE5 inhibitors is anticipated to decrease notably especially due to the market entry of generic versions of key oral drugs Viagra, Cialis and Levitra. The market for other drug therapy types, topical agents, intraurethral suppositories and intracavernosal injections, is anticipated to grow at a marginal rate. Increase in product uptake novel topical agent such as - Vitaros, increase in preferability of needle-free penile injection kits, increase in disease awareness are anticipated to boost the market growth of non-oral therapies in the forecast period.
The ED device therapy comprises of penile implants, vacuum erection devices, and others. The penile implants occupy the predominant share of the ED device market segment. Penile implants are the only available treatment modality which holds the potential to cure the disease. Penile implant surgeries are recommended as the last line of therapy as the procedure is invasive and is associated with severe risk factors. Vacuum erection devices also occupy a notable share of the market. The product uptake of these devices may likely be hindered in the foreseeable future due to the removal of Medicare coverage for these devices. Other device types such as vibrators, tension rings, and shockwave devices occupied a minor share of the market in 2018. However, this sub-segment is anticipated to post higher growth rate in comparison to other device types especially due to an increase in awareness of non-invasive device types.
The global ED market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The global market for ED is anticipated to witness a negative growth in the forecast period owing to patent expiry of key ED drugs Viagra, Cialis and Levitra. North America holds the major market share. It accounted for more than 45% of the market in 2018. Large disease population coupled with better access to ED treatments, high reimbursement coverage for high post penile implant surgeries in the US are few of the key factors for its high market share. The market value for ED is anticipated to fall significantly in the region owing to the loss of patent exclusivity of ED drugs.
APAC accounts for the third largest share of the global market. Low treatment-seeking rates, high associated social stigma in selected regions, low disease awareness and comparatively low access to healthcare services especially in developing countries are few factors limiting the market growth in the region. However, the market is anticipated to grow at a moderate pace in the forecast period. High disease prevalence population, rise in healthcare spending, increase in ED awareness, increase in uptake of ED drugs will boost ED market growth in this region.
The market for is ED drugs is oligopolistic, as a limited number of players account for the predominant market share. The ED drugs segment is dominated by key global players such as Pfizer, Eli Lilly, and Bayer. The two companies which occupy the major share of the ED devices segment include Coloplast and Boston Scientific.
The competitive landscape of both ED drugs and devices is highly dynamic with robust strategic activities. The ED drug manufacturers are highly focused on enhancing geographical outreach by the formation of agreements with local vendors in various regions. For instance - Dong-A Pharmaceutical, the manufacturer of ED drug - Zydena, formed an exclusive in-license agreement with Tabuk Pharmaceutical Manufacturing Company, a key pharmaceutical company in the MENA region. Vivus, the manufacturer of Stendra, formed a license agreement with Metuchen Pharmaceuticals to commercialize Stendra in the US, Canada, South America, and India.
ED device manufacturers are focused on strategic mergers and acquisitions for increasing their market competitiveness. For instance, in 2015, Boston Scientific acquired American Medical Systems' (AMS) Men's Health and Prostate Health businesses, for $1.6 billion in up-front cash and a potential additional $50 million milestone based on 2016 sales. The device manufacturers are also focused on development and marketing of novel non-invasive device types such as linear shockwave treatments, which hold the potential to cure the disease.